RxDoctor Payments Data

Haley Mitchell

Nurse Practitioner · Ada, OKNPI 1033760970

Payments from drug & device makers

$2,991in general payments, 2019–2025

Across 95 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • Novo Nordisk$400
  • Lilly USA, LLC$187
  • Teva Pharmaceuticals USA, Inc.$133
  • Neurocrine Biosciences, Inc.$99
  • AstraZeneca$87
  • plus $741 from 23 others

What the payments were for

  • Travel & lodging$94832%
  • Food & beverage$2,04368%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,991 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$26,921
Medicare patients
261
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymbicortBudesonide/Formoterol Fumarate16$3,534
Propranolol Hcl21$576
Methylprednisolone62$471
CefuroximeCefuroxime Axetil19$435
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$386
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$360
Albuterol Sulfate HfaAlbuterol Sulfate16$334
Azithromycin69$332
Doxycycline Hyclate32$282
Pantoprazole Sodium12$252
Levothyroxine Sodium11$231
Fluticasone Propionate11$204
Cephalexin34$166
Ciprofloxacin Hcl16$151
Prednisone77$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$87$3,53416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →